Curability of metastatic cancer: a survey of medical oncologists
JNCI Cancer Spectrum · 2026
DOI: 10.1093/jncics/pkaf115 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI Cancer Spectrum, 2026. Verfasst von Shalini Subramaniam und 3 weiteren Autor:innen. Beteiligte Einrichtung: NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia. Hauptthemen laut MEDLINE: Oncologists, Neoplasms, Attitude of Health Personnel. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian National Health and Medical Research Council (NHMRC) Clinical Trials Centre.
Abstract (Originalsprache)
Background
Patients with metastatic cancer are living longer due to treatment advances. We explored oncologists’ perceptions about curability in metastatic cancer.
Methods
We invited medical oncologists to complete a 21-item online survey. We conducted descriptive analyses and thematically analyzed free-text responses.
Results
A total of 126 respondents completed the survey. The median age was 39 years (range = 27-75). Most respondents worked in Australian (64%), metropolitan (88%), public practices (56%). The most frequently treated cancer types were breast (55%), lung (52%), and colorectal (50%). In total, 82% reported thinking that patients with metastatic cancer can be cured. Cancer types with the highest perceived chance of cure (median percentage) were testicular (81%), melanoma (32%), and colorectal (16%). At the time of diagnosis of metastatic cancer, 51% reported they would tell a patient that cure was possible. After treatment, 29% reported telling some patients they had been cured, whereas 74% reported telling some patients that they may have been cured. A higher proportion thought cure was a realistic possibility with immunotherapy (83%) rather than chemotherapy (40%), but only 44% and 27%, respectively, reported they would tell this to patients. In total, 46% reported discussing the possibility of cure more frequently with immunotherapy, 5% more frequently with chemotherapy, 7% as frequently with both, and 42% not discussing with either. Respondents identified oligometastatic disease, actionable mutations, and durable responses to immunotherapy as factors associated with cure.
Conclusions
Most respondents reported thinking that metastatic cancer is curable but were reluctant to tell individual patients with metastatic cancer they had been cured.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia.
- Bankstown-Lidcombe Hospital, Bankstown, NSW, Australia.
- Concord Cancer Centre, Concord, NSW, Australia.
- Macarthur Cancer Therapy Centre, Campbelltown, NSW, Australia.
ORCID-Profile: Shalini Subramaniam, Kim Tam Bui, Martin R Stockler, Belinda E Kiely
Förderung
- Australian National Health and Medical Research Council (NHMRC) Clinical Trials Centre
Zitieren
APA
Subramaniam, S., Bui, K. T., Stockler, M. R., & Kiely, B. E. (2026). Curability of metastatic cancer: a survey of medical oncologists. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkaf115
Vancouver
Subramaniam S, Bui KT, Stockler MR, Kiely BE. Curability of metastatic cancer: a survey of medical oncologists. JNCI Cancer Spectrum. 2026. doi:10.1093/jncics/pkaf115
BibTeX
@article{Subramaniam2026,
author = {Subramaniam, Shalini and Bui, Kim Tam and Stockler, Martin R and Kiely, Belinda E},
title = {Curability of metastatic cancer: a survey of medical oncologists},
journal = {JNCI Cancer Spectrum},
year = {2026},
doi = {10.1093/jncics/pkaf115}
}
EUVIMED